Skip to main content

Errata - English

PDF CSV April 29, 2022 through April 29, 2024 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Sort descending Description
POVIDONE IMPURITIES/Limit of Aldehydes USP35–NF30 4379 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 15 of Analysis: Change
Result = 10 × (C/W) × {[(AU2AU1) × (AB2AB1)]/[(AS2AS1) − (AB2 Read More
MICROCRYSTALLINE CELLULOSE IDENTIFICATION/B. Procedure USP35–NF30 1746 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 4th formula of Analysis: Change
Result = (95) × [η]c/WS × [(100 − %LOD)/100]
to:
Result = [(95) × [η]c]/{WS × [(100 − %LOD)/100]}
OMEGA-3-ACID ETHYL ESTERS CAPSULES SPECIFIC TESTS/Microbial Enumeration Tests <61> and Tests for Specified Microorganisms <62> First Supplement to USP35–NF30 5524 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2: Change
103
to:
103 cfu/mL
AND
Line 3: Change
102
to:
102 cfu/mL
AND
Line 6: Change
Salmonella in 10 g.
to:
Salmonella species in 10 g.
ALPRAZOLAM ORALLY-DISINTEGRATING TABLETS IMPURITIES/Procedure USP35–NF30 2106 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Change the subsection
Buffer and Diluent: Prepare as directed in the Assay.
to:
Diluent: Prepare as directed in the Assay.
Buffer: 6.8 g/L of monobasic potassium phosphate in water. Adjust with phosphoric acid to a pH of 3.0.
POVIDONE IMPURITIES/Vinylpyrrolidinone USP35–NF30 4379 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2 of the Note in Column, Analytical in Chromatographic system: Change
4.0- × 30-mm or a 4.6- × 30-mm guard column
to:
4.0-mm × 30-mm or a 4.6-mm × 30-mm guard column
MAGNESIUM STEARATE IMPURITIES/Chloride and Sulfate, Sulfate <221> USP35–NF30 1847 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 3: Change
0.020 N sulfuric acid (1.0%)
to:
0.020 M sulfuric acid (1.0%)
TACROLIMUS IMPURITIES/Procedure 2 First Supplement to USP35–NF30 5538 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Footnote h of Table 3: Change
(3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-… Read More
AMOXICILLIN TABLETS PERFORMANCE TESTS USP35–NF30 2202 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 4 of Analysis: Change
Result = (rU/rS) × (CS/L) × (D/V) × P × F × 100
to:
Result = (rU/rS) × (CS/L) × V × D × P × F × 100
AND
Transpose lines 12 and 13 of the variable definition list to match the order… Read More
PRILOCAINE AND EPINEPHRINE INJECTION Assay for epinephrine USP35–NF30 4411 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 7 of Procedure: Change
183.21/333.30
to:
183.20/333.29
AND
Line 8 of Procedure: Change
183.21 and 333.30
to:
183.20 and 333.29
METHYL ALCOHOL ASSAY/Procedure USP35–NF30 1865 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 9 of System suitability: Change
Tailing factor: NLT 1.5 for methyl alcohol, System suitability solution
to:
Tailing factor: NMT 1.5 for methyl alcohol, System suitability solution
TACROLIMUS CAPSULES IMPURITIES/Procedure 2 First Supplement to USP35–NF30 5541 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Footnote j of Table 5: Change
(3S,4R,5S,8S,9E,12S,14S,15R,16S,18R,19R,26aS)-5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a-hexadecahydro-5,19-dihydroxy-3-{(E)-2-[(1R,3R,4R)-4-… Read More
CHLOROPHYLLIN COPPER COMPLEX SODIUM SPECIFIC TESTS/Loss on Drying <231> USP35–NF30 2628 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1: Change
150°
to:
105°
RIBAVIRIN TABLETS ASSAY/Procedure USP35–NF30 4544 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5 of System suitability in subsection Tailing factor: Change
NLT 2.0
to:
NMT 2.0
POLYETHYLENE OXIDE IMPURITIES/Organic Impurities/Procedure: Limit of Free Ethylene Oxide USP35–NF30 1906 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2 of System suitability: Change
Samples: Standard stock solution and Standard solution C
to:
Sample: Standard solution C
<232> ELEMENTAL IMPURITIES—LIMITS DRUG SUBSTANCE AND EXCIPIENTS Second Supplement to USP35–NF30 5633 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Rows 11 and 15 of Column 2 of Table 2: Change
100
to:
10
AND
Rows 11 and 15 of Column 3 of Table 2: Change
10
to:
1.0
AND
Row 11 of Column 4 of Table 2: Change
1.5
to:
0.15
AND
Row 15 of Column 4 of Table 2:… Read More
FLUTICASONE PROPIONATE IMPURITIES/Organic Impurities USP35–NF30 3261 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of the Sample solution: Change
2.0 mg/mL
to:
0.2 mg/mL
TYROSINE IMPURITIES/Heavy Metals <231> USP35–NF30 4976 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1: Change
Method I
to:
Method II
POLYSORBATE 20 SPECIFIC TESTS/Acid Value USP35–NF30 1919 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample: Change
10.0
to:
10.0 g
<232> ELEMENTAL IMPURITIES—LIMITS ANALYTICAL TESTING Second Supplement to USP35–NF30 5633 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 6: Change
Pd
to:
Pb
GANCICLOVIR ORAL SUSPENSION ASSAY USP35–NF30 3319 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Internal standard solution: Change
4 mg per mL
to:
0.4 mg per mL
VINORELBINE TARTRATE ASSAY/Procedure USP35–NF30 5027 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Relative standard deviation in System suitability: Change
NLT 2.0%
to:
NMT 2.0%
POLYSORBATE 60 SPECIFIC TESTS/Acid Value USP35–NF30 1920 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample: Change
10.0
to:
10.0 g
<232> ELEMENTAL IMPURITIES—LIMITS DRUG SUBSTANCE AND EXCIPIENTS Second Supplement to USP35–NF30 5633 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Row 13 of Column 4 of Table 2: Change
25
to:
1.0
INDINAVIR SULFATE OTHER COMPONENTS/Procedure 2: Content of Alcohol USP35–NF30 3489 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 6 of Chromatographic system in the subsection Column: Change
G14
to:
G16
ZINC CARBONATE IMPURITIES/Iron <241> USP35–NF30 5068 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample solution: Change
Sample solution: Dissolve 1.0 g in 20 mL of water and 3 mL of hydrochloric acid.
to:
Test preparation: Dissolve 0.5 g in 20 mL of water and 3 mL of hydrochloric acid.
SODIUM HYDROXIDE ASSAY/Procedure USP35–NF30 1955 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 10 of Analysis: Change
Result = {[(VS1VB) × N × F1]/W} × 100
to:
Result = {[(VS2VB) × N × F1]/W} × 100
AND
Line 11 of Read More
<232> ELEMENTAL IMPURITIES—LIMITS DRUG PRODUCTS/Large Volume Parenterals Second Supplement to USP35–NF30 5633 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Row 13 of Column 4 of Table 1: Change
250
to:
10
Omega-3-Acid Ethyl Esters Capsules SPECIFIC TESTS/Microbial Enumeration <61> First Supplement to USP35–NF30 5524 1-Dec-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2: Change
103
to:
103 cfu/g
AND
Line 3: Change
102
to:
102 cfu/g
METFORMIN HYDROCHLORIDE TABLETS Dissolution <711>/Test 3 USP35–NF30 3830 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Lines 6 and 7 of Procedure: Change
rU × CS × 900 × 100/rS × D × LC
to:
rU × CS × 1000 × 100/rS × D × LC
AND
Line 11 of Procedure:… Read More
<698> DELIVERABLE VOLUME ACCEPTANCE CRITERIA/For Multiple-Unit Containers First Supplement to USP35–NF30 5154 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Figure 1, right branch, left box: Change
Volume of 1 more containers is less than 95% LV
to:
Volume of 1 or more containers is less than 95% LV
DESCRIPTION AND SOLUBILITY Ethylcellulose Dispersion Type B USP35–NF30 1118 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Lines 3 and 4: Change
in toluene, in chloroform, and in ethyl acetate; insoluble in water, in glycerin, and in propylene glycol.
to:
in tetrahydrofuran, and in ethyl acetate; insoluble in water and in chloroform.
TREHALOSE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP35–NF30 2007 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2: Delete
USP Glycerin RS
<233> ELEMENTAL IMPURITIES—PROCEDURES INTRODUCTION/Definition Second Supplement to USP35–NF30 5634 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2 of Target Elements: Change
Pd
to:
Pb
METRONIDAZOLE Related compounds USP35–NF30 3905 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 19 of Procedure: Change
ri is the peak response for any unspecified degradation product peak in the Test solution
to:
ri is the peak response for any single unspecified impurity in the Test solution
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 3 First Supplement to USP35–NF30 5460 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 2 of Analysis: Change
Samples: Acid stage standard solution, Buffer stage standard solution, Acid stage sample solutions, and Buffer stage sample solutions
to:
Samples: Acid stage standard solution, Buffer stage standard… Read More
BENTONITE IDENTIFICATION/A. X-Ray Diffraction <941> USP35–NF30 1705 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 4 of Acceptance criteria: Change
from the pattern of Sample B is 1.492 and 1.504 Å.
to:
from the pattern of Sample B is between 1.492 and 1.504 Å.
ZEIN IDENTIFICATION/C. SDS-Polyacrylamide Gel Electrophoresis USP35–NF30 2019 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Lines 1 and 2 of the Acceptance criteria: Change
Zein has two major bands: the α band is at 21–25 kDa, and the β band is at 17–18 kDa.
to:
Zein has two major bands for α-zein at 19–26 kDa.
AZITHROMYCIN FOR INJECTION IMPURITIES/Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3′-De(dimethylamino)-3′-oxoazithromycin Second Supplement to USP35–NF30 5910 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Row 11 of Table 2: Change
3′-Demethyl-3′-N-[(4-methylphenyl)sulfonyl]azithromycin
to:
3′-N-Demethyl-3′-N-[(4-methylphenyl)sulfonyl]azithromycin
NAFTIFINE HYDROCHLORIDE GEL Content of alcohol USP35–NF30 3983 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 4 of Procedure: Change
Calculate the quantity, in mg, of C2H5OH in the portion of Gel taken by the formula:
to:
Calculate the percentage of C2H5OH in the portion of Gel taken by the formula:
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES PERFORMANCE TESTS/Dissolution <711> First Supplement to USP35–NF30 5473 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 4 of Medium: Change
and adjust with 2 N hydrochloric acid or 2 N sodium, if necessary, to a pH
to:
and adjust with 2 N hydrochloric acid or 2 N sodium hydroxide, if necessary, to a pH
TRIBASIC CALCIUM PHOSPHATE IDENTIFICATION/Test A USP35–NF30 1719 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of the Sample solution: Change
Dissolve 100 mg in 5 mL of diluted nitric acid.
to:
A solution in a slight excess of nitric acid
ACETAZOLAMIDE FOR INJECTION ASSAY USP35–NF30 2063 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 19: Change
25C(AU/AS)
to:
250C(AU/AS)
AZITHROMYCIN FOR INJECTION IMPURITIES/Limit of Azithromycin N-Oxide, Desosaminylazithromycin, and N-Demethylazithromycin Second Supplement to USP35–NF30 5910 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5 of Analysis: Change
Result = (rU/rS) × (CS/CU) × P × F × 100
to:
Result = (rU/rS) × (CS/C Read More
POLYVINYL ALCOHOL Identification test C USP35–NF30 4351 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5: Change
Add 10 mL of alcohol to the remaining 5 mL of the polyvinyl alcohol solution, and mix
to:
Add 10 mL of alcohol to the remaining 2 mL of the polyvinyl alcohol solution, and mix.
ESOMEPRAZOLE MAGNESIUM DELAYED-RELEASE CAPSULES IMPURITIES/Organic Impurities First Supplement to USP35–NF30 5473 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1 of Sample solution: Change
Transfer a portion of the powdered pellets, from the Capsule content, equivalent to 80–90 mg of esomeprazole, to a 200-mL volumetric flask, add 20 mL of methanol, and shake for 30 s.
to:
Transfer a portion of the powdered pellets (about 80–90 mg… Read More
CALCIUM SULFATE ASSAY/Procedure USP35–NF30 1724 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 5 of Titrimetric system: Delete the subsection
Blank: 100 mL of water and 4 mL of 3 N hydrochloric acid
AND
Line 11 of Analysis: Delete the sentence
Perform a blank determination.
AND
Line 13 of Analysis: Change
Result = [(VB… Read More
ADENOSINE IDENTIFICATION/Infrared Absorption <197M> USP35–NF30 2079 1-Oct-2012 USP37–NF32 First Supplement to USP36–NF31 Line 1:
Delete NMT 0.1%
DILUTED ALCOHOL ADDITIONAL REQUIREMENTS USP36–NF31 1874 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 Delete USP Reference Standards <11> section
CALCIUM CARBONATE IMPURITIES USP36–NF31 2747 1-Aug-2013 USP38–NF33 First Supplement to USP37–NF32 Line 1 of Acceptance criteria in Limit of Fluoride: Change
50 ppm
to:
NMT 50 ppm
AND
Line 1 of Acceptance criteria in Mercury, Method IIa <261>: Change
0.5 ppm
to:
NMT 0.5 ppm
DROSPIRENONE IMPURITIES/Organic Impurities/Procedure 2 USP36–NF31 3349 1-Oct-2013 USP38–NF33 First Supplement to USP37–NF32 In footnote b of Table 4: Change
5β,17β-Dihydroxy-6β,7β:15β,16β-dimethylene-17α-pregnan-21-carboxylic acid, γ-lactone.
to:
5β,17-Dihydroxy-6β,7β:15β,16β-dimethylene-3-oxo-17α-pregnan-21-carboxylic acid, γ-lactone.